<DOC>
	<DOCNO>NCT00201123</DOCNO>
	<brief_summary>This study evaluate lung 's immune response mycobacterium tuberculosis ( Mtb ) infection modulate response interferon-gamma .</brief_summary>
	<brief_title>Effects Interferon-Gamma Cavitary Pulmonary Tuberculosis Lungs</brief_title>
	<detailed_description>BACKGROUND : Mtb infects one-third world 's population rank seventh term global morbidity mortality . Patients bilateral pulmonary tuberculosis ( TB ) , cavitary disease , persistently positive sputum smear pose special risk treatment failure and/or relapse . DESIGN NARRATIVE : Cavitary pulmonary TB study interferon-gamma use intervention . The outcome study change mycobacteriology , chest radiography , bronchoalveolar lavage ( BAL ) cell . The primary outcome sputum conversion , measure Weeks 4 8 . The key secondary outcome study include chest computerized tomography ( CT ) scan BAL measure flow cytometry cytokine level . Both outcome measure baseline Month 4 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Positive acidfast bacillus ( AFB ) smear within 14 day prior randomization Cluster Differentiation 4 great 200 HIV positive Ability sign consent Bilateral , cavitary pulmonary TB Multidrugresistant ( MDR ) TB Extrapulmonary TB HIV positive opportunistic infection within 30 day study entry Cancer Asthma Pregnant lactate woman Chronic heart disease Chronic liver disease Chronic renal disease Seizure disorder Bleeding clot disorder Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>